For employers wanting to dip a toe into the GLP-1 medications pool, utilization management is recommended to control costs.

Researchers evaluate the effects of glucagon-like peptide-1 receptor agonists on kidney and cardiovascular outcomes.

Nearly half of individuals consuming alcohol at baseline reduced their alcohol consumption following the initiation of AOMs.

A new weight loss drug called MariTide caused 20 percent weight loss in a recent trial, even better than Wegovy or Ozempic.

The biggest and most comprehensive analysis of glucagon-like peptide-1 (GLP-1) receptor agonists on kidney and cardiovascular ...

But for a long time China’s people struggled to get hold of Wegovy because the country’s regulators had not approved it. Some ...

A SYSTEMATIC review investigating the impact of glucagon-like peptide-1 receptor agonists on alcohol consumption has yielded ...

November is Diabetic Eye Disease Awareness Month. Diabetes is the leading cause of preventable blindness in the US. Here is a ...

Compared with standard AUD medications, the use of semaglutide and liraglutide was linked to a lower risk for alcohol use ...

In a randomized controlled trial of people with type 2 diabetes, albuminuria, and estimated glomerular filtration rate (eGFR) ...

A recent groundbreaking study found that Glucagon-like peptide 1 receptor agonists (GLP1-RA) are effective in reducing venous ...